Place it in its market
Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.
See how Context works →On the price, the facts of the public record■Insider buy□Insider sell●Results filed
With an account, also○dividends▲splits◌next earningswith an account
End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.
Latest on record
The most recent facts, as filed.
Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.
- Oct 14, 2026Reported sale · Form 4Samarth Kulkarni, Chief Executive Officer · $201.9KOpen the filing ↗
- Oct 14, 2026Reported sale · Form 4JAMES R. KASINGER, General Counsel and Secretary · $51.2KOpen the filing ↗
- Oct 14, 2026Reported sale · Form 4Simeon George · $720.4KOpen the filing ↗
In numbers
What this profile holds, counted.
Closes · 1 year250
SEC filings on record83618 flagged findings
Reported transactions (Form 4)80since Feb 18, 2026 · and 17 other holdings
Corporate events (8-K)30since Dec 16, 2019
What the record says
Description, identity and filings, each with its source.
Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.
What the company does
CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. The company does business as CRISPR Therapeutics, Inc. in the United States. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland; Boston, Massachusetts; San Francisco, California; and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts, won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.
Source: Wikipedia (CC BY-SA 4.0) · copied on Sep 3, 2026 · may not reflect recent changes.
Regulatory history
Topics detected in its SEC reports, with the original excerpt.
Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.
- 2026-05-04share offering or dilution eventrecentOpen filing ↗“…or the expiration of the capital band if earlier, up to an upper limit of CHF 3,197,637.93 by issuing a corresponding number of…”
+1 more passage from the same document
- “…received net proceeds from the 2026 Note Offering of approximately $585.4 million, after deducting the initial purchasers’…”
- 2026-05-04capital return (buybacks/dividends)recentOpen filing ↗“…amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the optional redemption date. No…”
+1 more passage from the same document
- “…but excluding, the optional redemption date. No sinking fund is provided for the Notes. If the Company undergoes a fundamental…”
- 2026-03-16share offering or dilution eventrecentOpen filing ↗“…complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item…”
+1 more passage from the same document
- “…statements contained in this press release, other than to the extent required by law. Item 9.01. Financial Statements and…”
- 2026-03-16capital return (buybacks/dividends)recentOpen filing ↗“…amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the optional redemption date. No…”
+1 more passage from the same document
- “…but excluding, the optional redemption date. No sinking fund is provided for the Notes. If the Company undergoes a fundamental…”
Original excerpts from SEC filings, untranslated. Not advice and not a prediction.
The 25 most recent filings (of 836)
Every SEC filing, newest first, with what it is. Below, each type with its own explanation.
- Oct 14, 26Form 144 ↗Notice of proposed sale new
- Oct 8, 26Form 4 ↗Insider transaction
- Oct 6, 26Form 144 ↗Notice of proposed sale
- Sep 24, 26Form 4 ↗Insider transaction
- Sep 22, 26Form 144 ↗Notice of proposed sale
- Sep 17, 26Form 144 ↗Notice of proposed sale
- Aug 14, 26SCHEDULE 13G/A ↗Passive stake · ORBIS INVESTMENT MANAGEMENT LTD · 5.6% · event on Jun 30, 26 · amendment
- Aug 11, 26Form 4 ↗Insider transaction
- Aug 3, 2610-Q ↗Quarterly report
- Aug 3, 268-K ↗Current report · Results
- Jul 27, 26SCHEDULE 13G/A ↗Passive stake · BlackRock, Inc. · 8.3% · event on Jun 30, 26 · amendment
Insider transaction · 9 Form 4 filingsshow all 9hide
- Jun 9, 26Form 4 ↗Insider transaction
- Jun 9, 26Form 4 ↗Insider transaction
- Jun 9, 26Form 4 ↗Insider transaction
- Jun 9, 26Form 4 ↗Insider transaction
- Jun 9, 26Form 4 ↗Insider transaction
- Jun 9, 26Form 4 ↗Insider transaction
- Jun 9, 26Form 4 ↗Insider transaction
- Jun 9, 26Form 4 ↗Insider transaction
- Jun 9, 26Form 4 ↗Insider transaction
836 filings on record, the oldest from Jun 13, 16.
Listing the 25 most recent filings of the 836 on record.
2326
- Jun 4, 26A senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
- Mar 16, 26Entered a material agreement+3 more in the same filing8-K 1.01 ↗
- May 19, 25Entered a material agreement+2 more in the same filing8-K 1.01 ↗
3 senior executive changes2024 – 2025show all 3hide
- Mar 26, 25A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jun 3, 24A senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
- May 23, 24A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Feb 13, 24Entered a material agreement+1 more in the same filing8-K 1.01 ↗
- Dec 19, 23A senior executive left or was appointed8-K 5.02 ↗
- Dec 13, 23Entered a material agreement+1 more in the same filing8-K 1.01 ↗
3 senior executive changes2023show all 3hide
- Sep 7, 23A senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
- Jun 9, 23A senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
- Mar 29, 23A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Mar 27, 23Entered a material agreement+2 more in the same filing8-K 1.01 ↗
5 senior executive changes2021 – 2023show all 5hide
- Mar 14, 23A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Oct 27, 22A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Jun 13, 22A senior executive left or was appointed+3 more in the same filing8-K 5.02 ↗
- Dec 20, 21A senior executive left or was appointed8-K 5.02 ↗
- Oct 14, 21A senior executive left or was appointed+1 more in the same filing8-K 5.02 ↗
- Apr 20, 21Entered a material agreement+2 more in the same filing8-K 1.01 ↗
- Jul 2, 20Entered a material agreement+2 more in the same filing8-K 1.01 ↗
5 older filings not shown · The record reaches back to Dec 16, 16.
Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.
Schedule 13G: short-form filing
The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.
- ARK Investment Management LLC11.8%Mar 31, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 4 earlier filings
- BlackRock, Inc.8.3%Jun 30, 26SCHEDULE 13G/A ↗1 earlier filing
- ORBIS INVESTMENT MANAGEMENT LTD5.6%Jun 30, 26SCHEDULE 13G/A ↗2 co-filers on this document — the figure is the largest single stake, not their sum. · 3 earlier filings
- Capital World Investors5.1%Mar 31, 26SCHEDULE 13G ↗
- Capital International Investors1.2%Jan 30, 26SCHEDULE 13G/A ↗1 earlier filing
Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.
Sale intention announced
On Oct 14, SIMEON GEORGE filed notice of intent to sell up to $720K. That is about 0.02% of shares outstanding.
A notice is not a sale: it may not go ahead, may happen in part, or at a different price.
After the notice, they sold $720K on Oct 14, per their Form 4. That is 100% of the shares announced so far, and the window is still open.
View notice (Form 144) ↗+3 more recent notices · 3 with a later sale
- Oct 14, 26Sell$202KSamarth KulkarniChief Executive Officer↗
- Oct 14, 26Sell$51KJAMES R. KASINGERGeneral Counsel and Secretary↗
- Oct 14, 26Sell$720KSimeon George↗
- Oct 6, 26Sell$119KJAMES R. KASINGERGeneral Counsel and Secretary↗
- Sep 22, 26Sell$626KJAMES R. KASINGERGeneral Counsel and Secretary↗
- Sep 17, 26Sell$781KAli Behbahani↗
- May 29, 26Sell$211KNaimish PatelChief Medical Officer↗
- Mar 23, 26Sell$173KRaju PrasadChief Financial Officer↗
- Mar 23, 26Sell$469KSamarth KulkarniChief Executive Officer↗
- Mar 23, 26Sell$149KJAMES R. KASINGERGeneral Counsel and Secretary↗
- Mar 16, 26Sell$499KSamarth KulkarniChief Executive Officer↗
- Mar 16, 26Sell$166KJAMES R. KASINGERGeneral Counsel and Secretary↗
There are 7 more transactions in this stretch.
Stock compensation, tax and giftsshow the 21 other transactionshide
Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.
- Oct 14, 26Compensation$420KSimeon George↗
- Oct 13, 26Compensationamount n/aSamarth KulkarniChief Executive Officer↗
- Oct 13, 26Compensationamount n/aJAMES R. KASINGERGeneral Counsel and Secretary↗
- Oct 6, 26Compensation$27KJAMES R. KASINGERGeneral Counsel and Secretary↗
- Sep 22, 26Compensation$142KJAMES R. KASINGERGeneral Counsel and Secretary↗
- Sep 17, 26Compensation$420KAli Behbahani↗
- Aug 7, 26Giftamount n/aRaju PrasadChief Financial Officer↗
- May 28, 26Compensationamount n/aNaimish PatelChief Medical Officer↗
- Mar 20, 26Compensationamount n/aRaju PrasadChief Financial Officer↗
- Mar 20, 26Compensationamount n/aSamarth KulkarniChief Executive Officer↗
- Mar 20, 26Compensationamount n/aJAMES R. KASINGERGeneral Counsel and Secretary↗
- Mar 16, 26Giftamount n/aRaju PrasadChief Financial Officer↗
- Mar 14, 26Compensationamount n/aSamarth KulkarniChief Executive Officer↗
- Mar 14, 26Compensationamount n/aJAMES R. KASINGERGeneral Counsel and Secretary↗
- Mar 14, 26Compensationamount n/aRaju PrasadChief Financial Officer↗
- Mar 14, 26Compensationamount n/aRaju PrasadChief Financial Officer↗
- Mar 14, 26Compensationamount n/aNaimish PatelChief Medical Officer↗
- Mar 10, 26Compensationamount n/aSamarth KulkarniChief Executive Officer↗
- Mar 10, 26Compensationamount n/aJAMES R. KASINGERGeneral Counsel and Secretary↗
- Feb 18, 26Compensationamount n/aJAMES R. KASINGERGeneral Counsel and Secretary↗
- Feb 18, 26Compensationamount n/aSamarth KulkarniChief Executive Officer↗
The full record holds 182 transactions and goes back to Jan 27, 23.
Its sector and its market
Crispr Therapeutics AG among Health Care companies
The profile shows what is on record. Context and Radar place the company among those of its sector and region.
Browse its neighbours
Other Health Care companies
With an account you also get
- The four engines — growth, trend, risk and context — each with its word and its score.
- The risk band and the sector phase.
- The company's fundamentals and accounts.
- Watchlist: your list of companies, with the «since you follow it» figure.
The research continues
The profile tells the story. The market sets the scene.
From Crispr Therapeutics AG, the path continues in the other areas. Each one is shown with its own example, named in its step.
See what deserves a closer look
Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.
See how Radar works →Keep the why
Follow Crispr Therapeutics AG in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.
See an example review →
Coverage
What sits behind this page.
Where each figure comes from and how far it reaches.
- Prices
- End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
- Series quality
- 250 clean closes in the period.
- SEC records
- 836 documents on file, from Jun 13, 2016 to Oct 16, 2026.
- Company description
- Wikipedia, read on Sep 3, 2026.
- This page
- Generated on Oct 19, 2026; refreshed through the day.
Start at your own pace
Explore first. Go deeper with access.
Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.
Compare plans →- No account
This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.
- Pro
What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.
- Pro+
Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.
Are the prices real time?
No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.
Which SEC documents appear here?
Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.
Why does a European company show no SEC records?
It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.
Before forming a view on a company,
read what is on record.
One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.